Detalhe da pesquisa
1.
Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection.
N Engl J Med;
387(21): 1957-1968, 2022 11 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36346079
2.
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Int J Cancer;
154(6): 1043-1056, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37994647
3.
Regional Differences in Clinical Presentation and Prognosis of Patients With Post-Sustained Virologic Response Hepatocellular Carcinoma.
Clin Gastroenterol Hepatol;
22(1): 72-80.e4, 2024 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37442316
4.
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Liver Int;
44(1): 113-124, 2024 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37789669
5.
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.
Liver Int;
44(5): 1108-1125, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38517286
6.
Kinetics of the hepatitis B core-related antigen and treatment responses in chronic hepatitis B patients treated with tenofovir alafenamide.
Hepatol Res;
2024 Apr 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38685853
7.
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
Hepatol Res;
54(4): 382-391, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37983642
8.
Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.
J Gastroenterol Hepatol;
39(5): 949-954, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38291715
9.
Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study.
J Gastroenterol Hepatol;
2024 Mar 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38480009
10.
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Oncology;
101(4): 270-282, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36455517
11.
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
Oncology;
101(10): 624-633, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37307798
12.
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
Oncology;
101(9): 542-552, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37552968
13.
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.
Oncology;
101(5): 283-291, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36657420
14.
Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma.
Hepatol Res;
53(2): 172-178, 2023 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36214071
15.
Clinical outcomes of antithrombin III-based therapy for patients with portal vein thrombosis: A retrospective, multicenter study.
Hepatol Res;
53(1): 51-60, 2023 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36136893
16.
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis.
Hepatol Res;
53(8): 737-748, 2023 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37020416
17.
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Hepatol Res;
53(10): 1031-1042, 2023 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37306040
18.
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
J Gastroenterol Hepatol;
38(8): 1389-1397, 2023 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37231943
19.
International multicenter validation of GES score for HCC risk stratification in chronic hepatitis C patients.
J Viral Hepat;
29(9): 807-816, 2022 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35657138
20.
Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice.
Hepatology;
74(2): 656-666, 2021 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33706421